Clover's $3B 2026 Target Plus 4.5-Star Boost Is the Real Repricing Trigger

$2.92B-$3B in 2026 revenue is Clover's key proof point

The signal is straightforward: if Clover hits $2.92 billion to $3.00 billion in 2026 revenue, investors will have stronger evidence that the company's model is working. Management did not just hold its prior outlook; it raised full-year 2026 guidance across all metrics. For this stock, execution matters more than narrative. The 2026 targets are the clearest test of whether Clover's wide-network, full-risk Medicare Advantage model can turn better care into better economics.

How the 4.5-Star rating changes the 2027 setup

The 2027 upside case starts with star ratings. CMS recalculated Clover's PPO Medicare Advantage contract ... to 4.5 Stars for payment year 2027, and updated guidance also shows Clover's HMO contract H8010 moving from 4.0 Stars to 4.5 Stars for 2027. That matters because the higher ratings improve eligibility for quality-linked payments and are expected to boost expected bonus payments for 2027. In other words, 2026 is the proof point, while better star ratings can strengthen flexibility and economics into 2027.